{"name":"AUROBINDO PHARMA USA","slug":"aurobindo-pharma-usa","ticker":"","exchange":"","domain":"aurobindopharmausa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-06-30","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-23","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV, HIV Infections)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-08-01","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-Infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}